Brinks Hofer Gilson & Lione's Allen R. Baum was quoted in the Triangle Business Journal article, "Licensing as alternative to investors tops CED agenda." The article detailed opinions about the climate for licensing drug candidates and the upcoming CED's annual Biotechnology Conference.